Inflammatory Breast Cancer (IBC) is one of the most aggressive forms of breast cancer—and it often doesn't present as a lump, leading to delayed diagnosis.
Join our educational webinar:
July 30
12 PM PT | 2 PM CT | 3 PM ET
Register: https://t.co/l59xmrXrTm
Even HP was not tolerable for me as maintenance treatment for HER2+ MBC. The patient community calls Perjeta “poo-jeta” for a reason!
Indefinite T-DxD is not realistic- survivors will have to contend with long term SEs of ADCs (think ❤️& liver fx) #ASCO25#bcsm
Is liquid biopsy useful in bone-only metastatic #breastcancer?
Surprise!
✅Pts w bone-only disease are just as likely to have detectable ctDNA
✅ctDNA tumor fraction remains prognostic in bone-only setting
https://t.co/y7PZBWLtS8
@FoundationATCG@OSUCCC_James@OhioStateMedOnc
Informed by @FedEx@FedExHelp that *irreplaceable* shipment of plasma donated by metastatic #breastcancer patients for #cancerresearch are sitting in same city as delivery address - but not delivered till tomorrow.
3 days for overnight dry ice shipment is unacceptable @Fedex.
We are very excited to welcome @KimrynRathmell as our next CEO @OSUCCC_James!
Brilliant physician-scientist, talented administrator, dedicated mentor - we are so excited for what is to come!
I’m honored to serve as the next CEO of the @osuccc_james & look forward to joining my new Buckeye colleagues at @osuwexmed & @ohiostate to take bold steps to advance the future of oncology across Ohio & nationally. Check out my LinkedIn to learn more. https://t.co/Mr1dw4eUXX
Incredible to have @StoverLab giving a keynote lecture at the Harvard Breast and Gynecologic Cancer Symposium- what a thoughtful and practical approach to translational research in breast cancer
The @df_hcc Breast & Gynecologic Cancer Symposium started off with the J. Dirk Iglehart, M.D., Visiting Scholar Lecture given by Dr. Daniel Stover (@StoverLab) who discussed Translational Cancer Research: Data is the Answer and the Question.
https://t.co/v0dz4ywCjI